Pre-Conference Planner(s)
-
-
Petra Jacobs, MD
Addiction Medicine Team Leader
NIDA/Center for the Clinical Trials Network
-
Pre-Conference Speaker(s)
-
WL
Walter Ling, MD
Professor Emeritus
UCLA -
Michelle Lofwall, MD
Associate Professor of Behavioral Science and Psychiatry, Bell Alcohol and Addictions Chair, Medical Director of First Bridge and Straus Clinics
University of Kentucky College of Medicine/Center on Drug and Alcohol Research -
Katharina Wiest, PhD
Director of Research
CODA, Inc.
This session addresses the effectiveness of long-acting weekly and monthly subcutaneous buprenorphine extended-release (BUP-XR) medications used to treat adults with moderate to severe dependence to prescription or illegal opioids. The three forms of buprenorphine extended-release medications include: 1) BUP-XR subcutaneous monthly injection, 2) subcutaneous weekly and monthly injection, and 3) the buprenorphine implant. This range of weekly and monthly dosing options allows health care providers to have the ability to individualize treatment for patients.
Learning Objectives:
- Upon completion, participants will be able to describe the expansion of current medication treatment options for opioid use disorder.
- Upon completion, participants will be able to define three forms of extended-release buprenorphine medications.
- Upon completion, participants will be able to provide information about a range of weekly and monthly dosing options that allow for individualized treatment for patients.
